SCHEMBL5535976

SCHEMBL5535976

FC(F)(F)Oc1cccc(CNc2cc[c]cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
KDM5B Q9UGL1 1/20 0.48
P2RX7 Q99572 1/20 0.47
KCNN3 Q9UGI6 1/20 0.47
MAPK14 Q16539 1/20 0.46
GRM2 Q14416 1/20 0.45
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
MEN1 O00255 4/20 0.44
MAPT P10636 4/20 0.44
KMT2A Q03164 4/20 0.44
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 2/20 0.44
THRB P10828 2/20 0.44
PKM P14618 2/20 0.44
BLM P54132 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545910 0.89 MAPT (0.42) KDM5AKDM4CKDM5BP2RX7KCNN3
SCHEMBL5546744 0.87 CNR1 (0.51) KDM5AKDM4CKDM5BMAPK14CARM1
SCHEMBL5543662 0.82 HDAC1 (0.51) P2RX7KCNN3MEN1MAPTKMT2A
SCHEMBL4776208 0.81 KDM5A (0.47) KDM5AKDM4CKDM5BP2RX7KCNN3
SCHEMBL5536027 0.81 HIF1A (0.59) MEN1MAPTKMT2ARAB9AALDH1A1
SCHEMBL5537388 0.79 MAPT (0.52) CYP3A4CYP2C9CYP2C19MEN1MAPT
SCHEMBL3277993 0.79 USP28 (0.47) KDM5AKDM4CKDM5BP2RX7KCNN3
SCHEMBL8348536 0.79 PRMT6 (0.59) KDM5AKDM4CKDM5BP2RX7KCNN3
SCHEMBL29373647 0.79 PRMT6 (0.59) KDM5AKDM4CKDM5BP2RX7KCNN3
SCHEMBL3282376 0.78 MAPK14 (0.59) KDM5AKDM4CKDM5BMAPK14TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM5A 4851/4885KDM4C 4636/4885KDM5B 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.